Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186877 | 1.00 | KMT2A (0.48) | KMT2ACA12CA9ALDH1A1POLB | |
| SCHEMBL2909670 | 0.89 | CYP3A4 (0.51) | KMT2ACA12CA9POLBSMN1; SMN2 | |
| SCHEMBL8489619 | 0.85 | CA12 (0.47) | KMT2ACA12CA9POLBSMN1; SMN2 | |
| SCHEMBL1058567 | 0.82 | MMP9 (0.40) | KMT2APOLBHDAC1HDAC7 | |
| SCHEMBL3183424 | 0.82 | SMN1; SMN2 (0.41) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3749007 | 0.82 | SMN1; SMN2 (0.46) | KMT2ACA12CA9POLBSMN1; SMN2 | |
| SCHEMBL4750336 | 0.80 | GLS (0.50) | ALDH1A1MAOBCASP3 | |
| SCHEMBL30793979 | 0.80 | GLS (0.50) | ALDH1A1MAOBSMN1; SMN2CASP3HDAC1 | |
| SCHEMBL1171415 | 0.77 | KMT2A (0.69) | KMT2ACA12CA9ALDH1A1 | |
| SCHEMBL1171410 | 0.77 | KMT2A (0.69) | KMT2ACA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652143-B2 | Cyclic ureas used as inhibitors of metalloproteases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-01-26 | — | — | US | disclosed |
| US-20080096918-A1 | NOVEL CYCLIC UREAS USED AS INHIBITORS OF METALLOPROTEASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096918-A1 | NOVEL CYCLIC UREAS USED AS INHIBITORS OF METALLOPROTEASES | ADAMTS1, ADAMTS13, ADAMTS5 | KMT2A 3952/4885CA12 426/4885CA9 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.